共 50 条
- [41] A first-in-human phase I study of U3-1287 (AMG 888), a HER3 inhibitor, in patients (pts) with advanced solid tumors.JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)Berlin, J.Keedy, V. L.Janne, P. A.Yee, L.Rizvi, N. A.Jin, X.Copigneaux, C.Hettmann, T.Beaupre, D. M.LoRusso, P.
- [42] A phase 1 dose-escalation study of the oral selective inhibitor of nuclear export (SINE) KPT-330 (selinexor) in patients (pts) with heavily pretreated non-Hodgkin lymphoma (NHL).JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)Gutierrez, MartinGoy, AndreByrd, John C.Flynn, Joseph M.Sorensen, MortenBrown, PeterGabrail, Nashat Y.Savona, MichaelFlinn, IanBaz, Rachid C.Shah, Bijal D.Stone, Richard M.Jacobsen, EricKukreti, VishalTiedemann, Roger E.Rashal, TamiMirza, Mansoor RazaShacham, SharonKauffman, MichaelKuruvilla, John
- [43] First-in-human phase 1/1b trial of the first-in-class bi-steric mTORC1-selective inhibitor RMC-5552 in patients with advanced solid tumorsMOLECULAR CANCER THERAPEUTICS, 2023, 22 (12)Schram, Alison M.Nagash, Abdul RafehHaura, Eric B.Riess, Jonathan W.Ulahannan, Susanna V.Ou, Sai-Hong I.Capasso, AnnaMunster, Pamela N.Cheng, Michael L.Gustafson, W. ClayBitman, BojenaKar, SumitWang, ZhicanTao, LinMeyerowitz, Justin G.Burns, Howard A.
- [44] Phase I, first-in-human trial of an oral VEGFR tyrosine kinase inhibitor (TKI) x-82 in patients (pts) with advanced solid tumorsJOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)Moore, Kathleen N.Jones, Suzanne FieldsKurkjian, CarlaArkenau, Hendrik-TobiasInfante, Jeffrey R.Pant, ShubhamBurris, Howard A.McMeekin, D. ScottGibbons, JayHarrow, KimberlyLiang, ChrisRamsey, SaraBendell, Johanna C.
- [45] First-in-human phase 1 trial (DRAGON) of SRK-181, a potential first-in-class selective latent TGFβ1 inhibitor, alone or in combination with anti-PD-(L)1 treatment in patients with advanced solid tumors.JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)Yap, Timothy A.Barve, Minal A.Gainor, Justin F.Weekes, Colin D.Bockorny, BrunoJu, YawenFaucette, RyanBilic, SanelaLee-Hoeflich, Si TuenSong, GuochenChyung, YungLegler, MichelleGan, LuBendell, Johanna C.
- [46] A first-in-class, first-in-human phase I trial of p28, a non-HDM2-mediated peptide inhibitor of p53 ubiquitination in patients with metastatic refractory solid tumors.JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)Richards, J. M.Warso, M. A.Mehta, D.Christov, K.Schaeffer, C. M.Yamada, T.Beattie, C. W.Bressler, L. R.Das Gupta, T. K.
- [47] Biomarker analyses from a phase I study of WNT974, a first-in-class Porcupine inhibitor, in patients (pts) with advanced solid tumorsCANCER RESEARCH, 2018, 78 (13)Rodon, JordiArgiles, GuillemConnolly, Roisin M.Vaishampayan, Ulkade Jonge, MajaGarralda, ElenaGiannakis, MariosSmith, David C.Dobson, Jason R.McLaughlin, MargaretSeroutou, AbdelkaderJi, YanDolan, SineadMorawiak, JenniferMoody, SusanJanku, Filip
- [48] Safety and antitumor activity of selinexor (KPT-330), a first-in -class, oral XPO1 selective inhibitor of nuclear export: A phase I study expanded with colon cancer cohort.JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)Mau-Soerensen, MortenRazak, Albiruni R. A.Mahipal, AmitMahaseth, HemchandraGerecitano, John F.Shacham, SharonYau, Cindy Y. F.Lassen, UlrikShields, Anthony FrankMcCauley, DilaraCooksey, JenniferTan, David Shao PengRashal, TamiShacham, EranLandesman, YosefPond, GregoryOza, Amit M.Kauffman, MichaelSiu, LillianMirza, Mansoor Raza
- [49] A phase I trial of GRN163L (GRN), a first-in-class telomerase inhibitor, in advanced solid tumorsJOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)Ratain, M. J.Benedetti, F. M.Janisch, L.Khor, S.Schilsky, R. L.Cohen, E. E.Maitland, M. L.Elias, L.LoRusso, P. M.
- [50] Phase II Results of Ara-C and Idarubicin in Combination with the Selective Inhibitor of Nuclear Export (SINE) Compound Selinexor (KPT-330) in Patients with Relapsed or Refractory AMLBLOOD, 2016, 128 (22)Fiedler, WalterHeuser, MichaelChromik, JoergThol, FelicitasBokemeyer, CarstenTheile, SusannLebkuechner, IsabellKranich, Anne L.